Figure 5

The Y355X mutant receptor does not inhibit the activity of wild-type PPARγ. (A) WT and Y355X receptors (1 and 15 ng respectively) were transfected into NIH 3T3 cells individually or in combination in the presence or absence of 5 μM rosiglitazone (Rosi). (B) NIH 3T3 cells were transfected with the combination of 1 ng of WT PPARγ and increasing amounts of either the WT (1–4 ng), the dominant/negative mutant V290M (1–4 ng) or the Y355X mutant receptor (1–15 ng) as indicated. Data are normalized to the transcriptional activity of 1 ng of WT receptor and are presented as means ± SD (n = 3).